Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD

Author(s): Raj H. Patel*, Pablo M. Pella, Naeem Haider and Renato Blanco

Volume 22, Issue 3, 2022

Published on: 21 January, 2022

Article ID: e011221198456 Pages: 4

DOI: 10.2174/1871526521666211201112410

Price: $65

Abstract

Background: The novel coronavirus disease 2019 (COVID-19) has led to a global pandemic since its emergence from Wuhan, China, in December of 2019. As research continues to evolve, there is a paucity of reports describing the management and treatment of COVID-19 in patients with acute kidney failure and End-Stage Renal Disease (ESRD). These patients have increased susceptibility to developing severe clinical symptoms from SARS-CoV-2 infection due to their underlying comorbidities. Remdesivir has emerged as a promising antiviral drug against SARS-CoV-2. However, data regarding the clinical benefits of remdesivir in patients with severe renal impairment is unavailable as they have been excluded from clinical trials due to the risk of sulfobutylether-β-cyclodextrin (SBECD) accumulation in patients with eGFR<30 ml/min per 1.73m2.

Case Presentation: We present the first case of a 47-year-old male with end-stage renal disease who was successfully treated with remdesivir during hospitalization for acute respiratory distress syndrome and respiratory failure arising from COVID-19. The worsening clinical progress of the patient despite intensive care and treatment with intravenous azithromycin therapy led to the decision to utilize remdesivir after a risk-benefit analysis, despite his eGFR being <15 ml/min per 1.73m2. Although the patient developed reversible hepatotoxicity, marked improvement of symptoms was observed after the five-day course of remdesivir was completed.

Conclusion: Our findings describe the first instance of compassionate use of remdesivir for the treatment of COVID-19 in the setting of end-stage renal disease, acute respiratory distress syndrome, and hypoxemic respiratory failure.

Keywords: ESRD, COVID-19, remdesivir, hemodialysis, chronic kidney disease, acute kidney injury, ARDS.

Graphical Abstract

[1]
Durvasula R, Wellington T, McNamara E, Watnick S. COVID-19 and kidney failure in the acute care setting: our experience from seattle. Am J Kidney Dis 2020; 76(1): 4-6.
[http://dx.doi.org/10.1053/j.ajkd.2020.04.001] [PMID: 32276031]
[2]
Rabb H. Kidney diseases in the time of COVID-19: major challenges to patient care. J Clin Invest 2020; 130(6): 2749-51.
[http://dx.doi.org/10.1172/JCI138871] [PMID: 32250968]
[3]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3]
[4]
Wang R, Liao C, He H, et al. COVID-19 in Hemodialysis patients: a report of 5 cases. Am J Kidney Dis 2020; 76(1): 141-3.
[http://dx.doi.org/10.1053/j.ajkd.2020.03.009] [PMID: 32240718]
[5]
Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97(5): 829-38.
[http://dx.doi.org/10.1016/j.kint.2020.03.005] [PMID: 32247631]
[6]
Goldfarb DS, Benstein JA, Zhdanova O, et al. Impending shortages of kidney replacement therapy for COVID-19 patients. Clin J Am Soc Nephrol 2020; 15(6): 880-2.
[http://dx.doi.org/10.2215/CJN.05180420] [PMID: 32345750]
[7]
Adamsick ML, Gandhi RG, Bidell MR, et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol 2020; 31(7): 1384-6.
[http://dx.doi.org/10.1681/ASN.2020050589] [PMID: 32513665]
[8]
Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence. Travel Med Infect Dis 2020; 35: 101647.
[http://dx.doi.org/10.1016/j.tmaid.2020.101647]
[9]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[10]
Sise ME, Baggett MV, Shepard JO, Stevens JS, Rhee EP. Case 17-2020: A 68-Year-old man with Covid-19 and acute kidney injury. N Engl J Med 2020; 382(22): 2147-56.
[http://dx.doi.org/10.1056/NEJMcpc2002418] [PMID: 32402156]
[11]
Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr 2020; 14(4): 641-8.
[http://dx.doi.org/10.1016/j.dsx.2020.05.018]
[12]
Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253: 117592.
[http://dx.doi.org/10.1016/j.lfs.2020.117592] [PMID: 32222463]
[13]
Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020; 585(7824): 273-6.
[http://dx.doi.org/10.1038/s41586-020-2423-5]
[14]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[15]
Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020; 178: 104786.
[http://dx.doi.org/10.1016/j.antiviral.2020.104786] [PMID: 32251767]
[16]
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9]
[17]
Kiser TH, Fish DN, Aquilante CL, et al. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care 2015; 19(1): 32.
[http://dx.doi.org/10.1186/s13054-015-0753-8] [PMID: 25645660]
[18]
Luke DR, Wood ND, Tomaszewski KE, Damle B. Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis. Nephrol Dial Transplant 2012; 27(3): 1207-12.
[http://dx.doi.org/10.1093/ndt/gfr472] [PMID: 21868395]
[19]
Lilly CM, Welch VL, Mayer T, Ranauro P, Meisner J, Luke DR. Evaluation of intravenous voriconazole in patients with compromised renal function. BMC Infect Dis 2013; 13: 14.
[http://dx.doi.org/10.1186/1471-2334-13-14] [PMID: 23320795]
[20]
Estiverne C, Strohbehn IA, Mithani Z, et al. Remdesivir in patients with estimated GFR <30 ml/min per 1.73 m2 or on renal replacement therapy. Kidney Int Rep 2021; 6(3): 835-8.
[http://dx.doi.org/10.1016/j.ekir.2020.11.025] [PMID: 33263094]
[21]
Pettit NN, Pisano J, Nguyen CT, et al. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? Clin Infect Dis 2020. ciaa1851.
[http://dx.doi.org/10.1093/cid/ciaa1851]
[22]
Thakare S, Gandhi C, Modi T, et al. Safety of remdesivir in patients with acute kidney injury or CKD. Kidney Int Rep 2021; 6(1): 206-10.
[http://dx.doi.org/10.1016/j.ekir.2020.10.005] [PMID: 33073066]
[23]
Aiswarya D, Arumugam V, Dineshkumar T, et al. Use of remdesivir in patients with covid-19 on hemodialysis: a study of safety and tolerance. Kidney Int Rep 2021; 6(3): 586-93.
[http://dx.doi.org/10.1016/j.ekir.2020.12.003] [PMID: 33354635]

Rights & Permissions Print Cite
Article Metrics
19
1
© 2025 Bentham Science Publishers | Privacy Policy